Torrent management avoided commenting on valuations or whether big-ticket acquisitions are on the cards during a call to discuss fiscal Q2 results, as it faced a volley of questions on the topic following media reports of its interest in acquiring Cipla. Meanwhile, the Brazil business posted handsome gains during the quarter, while the US business shrunk.

Torrent management avoided commenting on valuations or whether big-ticket acquisitions are on the cards during a call to discuss fiscal Q2 results, as it faced a volley of questions on the topic following media reports of its interest in acquiring Cipla. Meanwhile, the Brazil business posted handsome gains during the quarter, while the US business shrunk

Aurobindo’s acquisition of 15 brands from Pfizer and Viatris to gain entry to Indonesia marks a role reversal of sorts as Pfizer has been licensing generics from Aurobindo. Scrip takes a look at some of the opportunities and challenges in this growing Southeast Asian market.

The damage at one of Pfizer’s largest injectables facilities could lead to gains for a few Indian companies, analysts feel. However, regulatory risks, litigation pay-outs and other challenges will slow growth for domestic firms and Indian units of multinationals like Abbott and Pfizer in FY24, says rating agency ICRA as Q1 results begin coming in